Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 6/20 | 0.45 |
| ▸ | OXTR | P30559 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2159558 | 0.88 | AVPR1A (0.49) | AVPR1AOXTRMEN1KMT2AESR2 | |
| SCHEMBL16864998 | 0.87 | AVPR1A (0.40) | AVPR1AMEN1KMT2AESR2NR1H2 | |
| SCHEMBL12097232 | 0.86 | RORC (0.40) | AVPR1AESR2NR1H2USP30HDAC1 | |
| SCHEMBL12097185 | 0.86 | GPR119 (0.42) | AVPR1AMEN1KMT2AESR2NR1H2 | |
| SCHEMBL29716173 | 0.86 | RORC (0.40) | AVPR1AESR2NR1H2USP30HDAC1 | |
| SCHEMBL17930157 | 0.84 | GPR119 (0.42) | AVPR1AMEN1KMT2AESR2NR1H2 | |
| SCHEMBL15505675 | 0.84 | HDAC1 (0.43) | AVPR1AOXTRESR2NR1H2HDAC1 | |
| SCHEMBL29948788 | 0.84 | HDAC1 (0.43) | AVPR1AOXTRESR2NR1H2HDAC1 | |
| SCHEMBL30008913 | 0.83 | AVPR1A (0.53) | AVPR1AESR2NR1H2 | |
| SCHEMBL3223037 | 0.83 | AVPR1A (0.53) | AVPR1AESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332492-B2 | CD73 inhibitors and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-11332492-B2 | CD73 inhibitors and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-20210253621-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253621-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| CN-112638389-A | CD73 inhibitors and therapeutic uses thereof | 江苏恒瑞医药股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2020047082-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | Eternity Bioscience Inc. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253621-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | ENTPD5, ENTPD1, NT5E | AVPR1A 4419/4885OXTR 3942/4885MEN1 2006/4885 |
| US-11332492-B2 | CD73 inhibitors and therapeutic uses thereof | ENTPD5, ENTPD1, NT5E | AVPR1A 4419/4885OXTR 3942/4885MEN1 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.